Ushaanthy Ravindran, MD
Endocrinology, Diabetes & Metabolism · Sacramento, CANPI 1992237622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.
Across 220 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$894
- Novo Nordisk$772
- Dexcom, Inc.$639
- Corcept Therapeutics$612
- Boehringer Ingelheim$414
- Lilly USA, LLC$321
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,96497%
- Education$811%
- Gifts$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 42 | $894 |
| Novo Nordisk | 32 | $772 |
| Dexcom, Inc. | 13 | $639 |
| Corcept Therapeutics | 7 | $612 |
| Boehringer Ingelheim | 11 | $414 |
| Lilly USA, LLC | 16 | $321 |
| Mannkind Corporation | 9 | $290 |
| Radius Health, Inc. | 12 | $278 |
| Bayer | 12 | $262 |
| BETA Bionics, Inc. | 3 | $246 |
| AstraZeneca(2 entities) | 5 | $195 |
| Sanofi-aventis U.S. LLC | 8 | $155 |
| Aurinia Pharma U.S., Inc. | 6 | $140 |
| Xeris Pharmaceuticals, Inc. | 8 | $133 |
| Medtronic | 4 | $85 |
| Octapharma USA, Inc. | 3 | $79 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| Ascensia Diabetes Care US Inc. | 3 | $66 |
| AbbVie | 2 | $54 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Abbott | 2 | $48 |
| Genentech USA, Inc. | 2 | $38 |
| Fresenius Kabi USA, LLC | 1 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $31 |
| Sandoz | 1 | $25 |
| Embecta Corp. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$502
- DEXCOM G7 GSS (161)$433
- DEXCOM STELO GLUCOSE BIOSENSOR$310
- JARDIANCE$244
- Korlym$241
- Ozempic$124
- RYBELSUS$122
- Prolia$121
How this compares
$6,164 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 181 | $336,297 |
| JardianceEmpagliflozin | 159 | $217,049 |
| MounjaroTirzepatide | 107 | $213,885 |
| TrulicityDulaglutide | 47 | $83,375 |
| RybelsusSemaglutide | 22 | $47,387 |
| TradjentaLinagliptin | 17 | $22,286 |
| FarxigaDapagliflozin Propanediol | 17 | $21,136 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $20,814 |
| JanuviaSitagliptin Phosphate | 16 | $15,013 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $13,790 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $12,540 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $10,841 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $10,755 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $8,548 |
| SynthroidLevothyroxine Sodium | 85 | $8,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $772 | $383,683203 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $321 | $302,619186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $414 | $239,335176 claims |
| AstraZenecaFarxiga | $195 | $21,13617 claims |
| AbbVieSynthroid | $54 | $8,25285 claims |
| Sanofi-aventis U.S. LLCLantus | $155 | $1,47311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Sacramento
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.